Abstract 2126P
Background
The beneficial effects of exercise for cancer patients are well recognized but implemented exercise programs remain scarce, especially for patients during medical treatment. For that reason, we developed a supervised, personalized exercise concept for cancer patients, implemented into a clinical, oncological setting.
Methods
Cancer patients before, during or eventually after their medical treatment with an identified need for exercise could participate in a free of charge exercise intervention for at least three months at the University Hospital Cologne, Germany. We recorded demographic and medical data at enrolment and exercise adherence up to one year.
Results
A sample of n=1.660 patients attended the exercise program. The majority of patients were female (70%), under medical treatment (65%), diagnosed with breast cancer (40%), without metastasis or severe comorbidities (>70%) and on average 54 years old. The median time between diagnosis and exercise participation differed in patients during medical treatment (4 months), patients with metastasis (7 months) and cancer survivors (11 months). Almost one third (31%) discontinued exercise within the first two weeks of participation. Prolonged exercise (median: 19 weeks) was achieved by one third (32%) of the patients. The average exercise adherence was ∼1 session a week with <3% of patients reaching ≥2 sessions a week
Conclusions
To our knowledge, this is the worlds-first report of a professional, supervised exercise program tailored for cancer patients under medical treatment implemented into a clinical setting with >1.600 patients. We described the population that was referred to an exercise program, identified barriers to exercise participation and observed an important mismatch between recommendations and real-world exercise data. Exercise participation was engaged ≥4months after diagnosis and only a third of the patients exercised longer than three months. Almost all patients undercut the well-established exercise recommendations of ≥2 sessions a week. Future implementation concepts should optimize exercise initiation timely after diagnosis and adherence levels due to innovative exercise approaches.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
University Hospital of Cologne, Cologne, Germany.
Funding
German Cancer Aid.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2095P - Cancer rehabilitation program for cancer-related fatigue
Presenter: Aizhan Bekisheva
Session: Poster session 06
2096P - Morphine titration with intravenous patient-controlled analgesia for severe cancer pain (Mr.TIPS)
Presenter: Seok Jae Huh
Session: Poster session 06
2097P - Incidence, risk factors (RFs) and management of oral mucositis (OM) in patients (pts) treated with a fluoropyrimidines (FP)-based therapy (tp): A retrospective, monocentric experience
Presenter: Fiorella Manfredi
Session: Poster session 06
2098P - The impact of concomitant use of non-opioid analgesics and immune checkpoint inhibitors on survival in lung cancer patients: A Hong Kong population-based cohort study
Presenter: Zheng-Hao Ye
Session: Poster session 06
2099P - The role of ambulatory blood pressure measurement in TKI-induced arterial hypertension diagnosis
Presenter: Elina Khachaturian
Session: Poster session 06
2100P - An exploratory study of the efficacy and safety of hetrombopag in the treatment of thrombocytopenia induced by concurrent or sequential chemoradiotherapy
Presenter: Jun Wang
Session: Poster session 06
2101P - Bleeding Induced by ANtiCAncer drugs (BIANCA) used breast cancer
Presenter: Nicolas Janus
Session: Poster session 06
2102P - Changes in opioid usage after intrathecal morphine pump implantation in patients with terminal cancer (pilot study)
Presenter: Eun Joo Choi
Session: Poster session 06
2103P - Phase Ib, international, dose-escalation study to evaluate the safety, pharmacokinetics (PK) and efficacy of ST-617 a dithiolethione, for the attenuation of oral mucositis (OM) in patients receiving chemoradiation (CRT) for head & neck (H&N) cancer
Presenter: Daniel Osei-Fofie
Session: Poster session 06
2104P - Prevention of taxane chemotherapy induced nail changes and peripheral neuropathy by application of extremity cooling: A prospective single center study with intrapatient comparison
Presenter: Kristen Johnson
Session: Poster session 06